Detection and functional analysis of CD8+ T cells specific for PRAME: A target for T-cell therapy

Clinical Cancer Research

Volumn 12, Issue 10, 2006, Pages 3130-3136

  Griffioen, Marieke ^a   Kessler, Jan H ^a   Borghi, Martina ^a   Van Soest, Ronald A ^a   Van Der Minne, Caroline E ^a   Nouta, Jan ^a   Van Der Burg, Sjoerd H ^a   Medema, Jan Paul ^a   Schrier, Peter I ^a   Frederik Falkenburg, J H ^a   Osanto, Susanne ^a   Melief, Cornelis J M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE LYMPHOCYTIC LEUKEMIA; ADOPTIVE IMMUNOTHERAPY; ANTIGEN EXPRESSION; ARTICLE; CANCER CELL CULTURE; CANCER THERAPY; CD8+ T LYMPHOCYTE; CELL CLONING; CELL ISOLATION; CELLULAR IMMUNITY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSPOT ASSAY; HUMAN; HUMAN CELL; IMMUNOTHERAPY; MELANOMA; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANTIGENS, NEOPLASM; CD8-POSITIVE T-LYMPHOCYTES; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES; HLA-A ANTIGENS; HUMANS; IMMUNOTHERAPY; MELANOMA; SKIN NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 33744789369     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-2578     Document Type: Article

References (22)

1. Nestle FO, Alijagic S, Gilliet M, et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998;4: 328-32.
2. Rosenberg SA, Yang YC, Schwartzentruber DJ, et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998; 4:321-7.
3. Coulie PG, Karanikas V, Lurquin C, et al. Cytolytic T-cell responses of cancer patients vaccinated with a MAGE antigen. Immunol Rev 2002;188:33-42.
4. Thurner B, Haendle I, Roder C, et al. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 1999; 190:1669-78.
5. + cancers. Proc Natl Acad Sci U S A 2000; 97:12198-203.
6. Ikeda H, Lethe B, Lehmann F, et al. Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity 1997;6:199-208.
7. 'tVeer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:530-6.
8. Epping MT, Wang L, Edel MJ, et al. The human tumor antigen PRAME is a dominant repressor of retinoic acid receptor signaling. Cell 2005;122: 835-47.
9. Kessler JH, Beekman NJ, Bres-Vloemans SA, et al. Efficient identification of novel HLA-A(*)0201-presented cytotoxic T lymphocyte epitopes in the widely expressed tumor antigen PRAME by proteasome-mediated digestion analysis. J Exp Med 2001; 193:73-88.
10. Goselink HM, van Damme J, Hiemstra PS, et al. Colony growth of human hematopoietic progenitor cells in the absence of serum is supported by a proteinase inhibitor identified as anti-leukoproteinase. J Exp Med 1996;184:1305-12.
11. Bednarek MA, Sauma SY, Gammon MC, et al. The minimum peptide epitope from the influenza virus matrix protein. Extra and intracellular loading of HLA-A2. J Immunol 1991;147:4047-53.
12. Griffioen M, Borghi M, Schrier PI, et al. Detection and quantification of CD8(+) T cells specific for HLA-A*0201-binding melanoma and viral peptides by the IFN-gamma-ELISPOT assay. Int J Cancer 2001; 93:549-55
13. Matzinger P. The danger model: a renewed sense of self. Science 2002;296:301-5.
14. Kiertscher SM, Luo J, Dubinett SM, et al. Tumors promote altered maturation and early apoptosis of monocyte-derived dendritic cells. J Immunol 2000; 164:1269-76.
15. Menetrier-Caux C, Montmain G, Dieu MC, et al. Inhibition of the differentiation of dendritic cells from CD34(+) progenitors by tumor cells: role of interleukin-6 and macrophage colony-stimulating factor. Blood 1998;92:4778-91.
16. Loftus DJ, Castelli C, Clay TM, et al. Identification of epitope mimics recognized by CTL reactive to the melanoma/melanocyte-derived peptide MART-1 (27-35). J Exp Med 1996;184:647-57.
17. Valmori D, Scheibenbogen C, Dutoit V, et al. Circulating Tumor-reactive CD8(+) T cells in melanoma patients contain a CD45RA(+)CCR7(-) effector subset exerting ex vivo tumor-specific cytolytic activity. Cancer Res 2002;62:1743-50.
18. Pittet MJ, Valmori D, Dunbar PR, et al. High frequencies of naive Melan-A/MART-1-specific CD8(+) T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals. J Exp Med 1999;190:705-15.
19. Lee PP, Yee C, Savage PA, et al. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med 1999;5: 677-85.
20. + T cell immunity in disease progression of advanced stage melanoma patients. Clin. Cancer Res 2004;10:4754-60.
21. van Baren N, Chambost H, Ferrant A, et al. PRAME, a gene encoding an antigen recognized on a human melanoma by cytolytic T cells, is expressed in acute leukaemia cells. Br J Haematol 1998;102:1376-9.
22. Matsushita M, Ikeda H, Kizaki M, et al. Quantitative monitoring of the PRAME gene for the detection of minimal residual disease in leukaemia. Br J Haematol 2001;112:916-26.